Genetic polymorphism of hepatitis C virus and risk of hepatocellular carcinoma
Abstract
The aim of review. To estimate effect of genetic polymorphism of hepatitis C virus on risk of hepatocellular carcinomas (HCC).
Key points. Hepatocellular carcinoma is one of the most dreadful outcomes of chronic liver diseases, in particular — chronic hepatitis C (CHC). Now it is revealed, that frequency of HCC in patients with 1b genotype of hepatitis C virus (HCV) was significantly above, than other genotypes. In aminoacidic sequences analysis in patients with 1b genotype of HCV mutations with substitution of arginine to glycine in codon 70 (Glu 70) and leucine to methionine in codon 91 (Met 91) were revealed. Thus it is revealed, that mutant type Glu 70 is significantly more frequent in patients with HCC in comparison to CHC and liver cirrhosis, in older age groups, at elevation of serum level of gamma-glutamyltranspeptidase and aspartate aminotransferase. Frequency of mutant forms of 1b genotype is related to discovery of previously unknown protein of HCV — minicor-protein with absence of N-terminal of classical Cor-protein p21.
Conclusion. Early detection mutant Glu 70, Met 91 forms of HCV genotype 1b will provide prediction of HCC risk in CHC patients and to begin adequate etiological treatment for preventive maintenance of this dangerous complication intime.
About the Authors
S. N. Mammayev
Dagestan State Medical Academy
Russian Federation
Russian Federation
Mammayev Suleyman N — MD, PhD, professor, head of the chair of hospital course of internal diseases N 1
367000, Dagestan Republic,Mahachkala, Lenina sq,1.
A. M. Karimova
Dagestan State Medical Academy
Russian Federation
Russian Federation
Karimova Aminat M — MD, assistant-professor, chair of hospital course of internal diseases N 1
367000, Dagestan Republic,Mahachkala, Lenina sq,1.
References
1. Гепатоцеллюлярная карцинома (ГЦК): глобальная перспектива. Практические рекомендации. [Электронный ресурс]: Всемирная гастроэнтерологическая организация Доступ: http://www.worldgastroenterology.org/ hepatocellular-carcinoma.html
2. Ahmad J, Eng FJ, Branch AD. HCV and HCC: clinical update and a review of HCC-associated viral mutations in the core gene. Semin Liver Dis 2011; 31(4):347-55.
3. Akuta N, Suzuki F, Hirakawa M, et al. A matched casecontrolled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino ac id substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81(3):452-8.
4. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus cor region and genetic variation near the interleukin 28b gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52(2):421-9.
5. Akuta N, Suzuki F, Kawamura Y, et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Нepatology. 2007;46(5):1357-64.
6. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27(9):1485-91.
7. Asahina Y, Tsuchiya K, Tamaki N. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52(2):518-27.
8. Bruno S, Crosignani A., Maisonneuve P, et al. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46(5):1350-6.
9. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49 (suppl 5):72-84.
10. Chen HM, Tanaka N, Mitani Y, et al. Critical role for constitutive type I interferon signaling in the prevention of cellular transformation. Cancer Sci 2009; 100(3):44956.
11. Chen RF, Li ZH, Liu RY, et al. Malignant transformation of the cultured human normal biliary tract epithelial cells induced by hepatitis C virus core protein. Oncol Rep 2007; 17(1):105-10.
12. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155(4):323-31.
13. Eng FJ, Walewski JL, Klepper AL, et al. Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. J Virol 2009; 83(7):3104-14.
14. Enomoto N, Maekawa S. HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology 2010; 53(1):66-9.
15. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127 (suppl 5):35-50.
16. Fridman AL, Tainsky MA. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 2008; 27(46):5975-87.
17. Funaoka Y, Sakamoto N, Suda G, et al. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of Cor amino acids 70 and 91. J Virol 2011; 85 (12):5896-994.
18. Hashem B. Viral hepatitis and hepatocellular carcinoma. Viral hepatitis: five decades of progress and promises for the future. Postgraduate course. AASLD. 2010.
19. Hassan MM, Spitz MR, Thomas MB, et al. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol. 2009; 50(2):334-41.
20. Huang XX, McCaughan GW, Shackel NA, et al. Up-regulation of proproliferative genes and the ligand/ receptor pair placental growth factor and vascular endothelial growth factor receptor 1 in hepatitis C cirrhosis. Liver international 2007; 27(7):960-8.
21. Ikeda K, Marusawa H, Osaki Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007; 146(9):649-566.
22. Inoue M, Kurahashi N, Iwasaki M, et al. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale populationbased cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control. 20(5):741-50.
23. Inoue M, Yoshimi I, Sobue T, et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: aprospective study in Japan. J Natl Cancer Inst 2005; 97(4):293-300.
24. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140(4):1182-8.
25. Kobayashi M, Akuta N, Suzuki F, et al. Influence of aminoacid polymorphism in the cor protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol 2010; 82:41-8.
26. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroentrol Hepatol 2007; 22:108-11.
27. Kurahashi N, Inoue M, Iwasaki M, et al. Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women. Int J Cancer 2009; 124(7):1644-9.
28. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007; 132(5):1740-5.
29. Lee MH, Yang HI, Lu SN, et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol 2010; 28(30):4587-93.
30. Li ZH, Tang QB, Wang J, et al. Hepatitis C virus core protein induces malignant transformation of biliary epithelial cells by activating nuclear factor-kappaB pathway. J Gastroenterol Hepatol 2010; 25(7):1315-20.
31. Liver Cancer Incidence, Mortality and Prevalence Worldwide in 2008 Summary. GLOBOCAN 2008. Cancer fact sheet [Электронный ресурс] International agency for research on cancer. World health organization. Доступ: http://globocan.iarc.fr
32. Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associates with hepatitis C virus infection perturbs hepatic transforming growth factorbeta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007; 46(1):48-57.
33. Mazzanti R, Messerini L, Comin CE, et al. Liver angiogenesis as a risk factor for hepatocellular carcinoma development in hepatitis C virus cirrhotic patients. World Journal of Gastroenterology 2007; 13(37):5009-14.
34. McGivern DR, Lemon SM. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer Annu Rev Pathol 2009; 4:399-415.
35. Mori N, Imamura M, Kawakami Y, et al. Hiroshima Liver Study Group. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol 2009; 81(4):640-9.
36. Nakamoto S, Imazeki F, Fukaiet K, et al. Association between mutations in the cor region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. J Hepatol 2010; 52:72-8.
37. Nkontchou G, Bastard JP, Ziol M, et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol 2010; 53(5):827-33.
38. Ogura S, Akuta N, Hirakawa M, et al. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment. Intervirology 2009; 52(4):179-88.
39. Raimondi S, Bruno S, Mondelli MU, et al. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis J Hepatol; 2009; 50(6):1142-54.
40. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007; 96(7):1127-34.
41. Smirnova IS, Aksenov ND, Kashuba EV, et al. Hepatitis C virus core protein transforms murine fibroblasts by promoting genomic instability. Cell Oncol 2006; 28(4):177-90.
42. Surveillance, epidemiology, and end results (SEER) program SEER Start Datebase: incidence – SEER 9 Reg Reserch Data, Nov 2009 Sub (1973-2007), National Cancer institute, DCCPS, Surveillance research program cancer statistics branch, realesed april 2010, based on the November 2009 submission. 2010. Ref Type: Generic. (www.seer.cancer.gov).
43. Wurmbach E, Chen YB, Khitrov G, et al. Genomewide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45(4):938-47.
44. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100(16):1134-43.
Review
For citations:
Mammayev S.N., Karimova A.M. Genetic polymorphism of hepatitis C virus and risk of hepatocellular carcinoma. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(3):42-48. (In Russ.)
Views:
114
Email this article 
